Abstract: The present invention relates to methods of inhibiting a mammalian C-C chemokine receptor 3 protein (CCR3). The invention further relates to methods of treating an inflammatory disease or condition. Administration of a compound which inhibits or promotes CCR3 function to an individual in need of therapy provides a new approach to selective modulation of leukocyte function, which is useful in a variety of inflammatory and autoimmune diseases, or in the treatment of infections. As a major leukocyte chemokine receptor present in leukocytes such as eosinophils and lymphocytes, the receptor provides a key target for drug screening and design.